H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Positive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 Trial
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target
Biomea Fusion Is Maintained at Buy by D. Boral Capital
Biomea Fusion Price Target Maintained With a $128.00/Share by D. Boral Capital
Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction...